Polychemotherapy with Curcumin and Doxorubicin via Biological Nanoplatforms: Enhancing Antitumor Activity

• Main Authors: Milad Ashrafizadeh (Author), Ali Zarrabi (Author), Farid Hashemi (Author), Amirhossein Zabolian (Author), Hossein Saleki (Author), Morteza Bagherian (Author), Negar Azami (Author), Atefe Kazemzade Bejandi (Author), Kiavash Hushmandi (Author), Hui Li Ang (Author), Pooyan Makvandi (Author), Haroon Khan (Author), Alan Prem Kumar (Author)
• Format: Book
• Published: MDPI AG, 2020-11-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Doxorubicin (DOX) is a well-known chemotherapeutic agent extensively applied in the field of cancer therapy. However, similar to other chemotherapeutic agents such as cisplatin, paclitaxel, docetaxel, etoposide and oxaliplatin, cancer cells are able to obtain chemoresistance that limits DOX efficacy...